[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100351750":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":42,"responsibleParty":60,"collaborators":32,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":32,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":32,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":32,"overallStatus":45,"whyStopped":32,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dydrogesterone group","EXPERIMENTAL","Oral dydrogesterone 10mg tds will be given for two weeks from the next day of the LH surge or hCG induced ovulation.",[13],"Drug: Dydrogesterone",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Placebo will be given given for two weeks from the next day of the LH surge or hCG induced ovulation.",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dydrogesterone","Progesterone",[9],[27],"Duphaston",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Placebo with appearance similar to Dydrogesterone",[15],null,[34],{"name":35,"affiliation":5,"role":36},"Ernest HY Ng, MD","PRINCIPAL_INVESTIGATOR",[38],{"name":35,"role":39,"phone":40,"phoneExt":32,"email":41},"CONTACT","852-28553400","nghye@hku.hk",[43],{"facility":44,"status":45,"city":46,"state":46,"zip":32,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Department of Obstetrics and Gynaecology","RECRUITING","Hong Kong","China","CN",{"type":50,"coordinates":51},"Point",[52,53],114.17469,22.27832,{"lat":53,"lon":52},[56,59],{"name":57,"role":39,"phone":58,"phoneExt":32,"email":41},"Ernest HY NG, MD","852-22553400",{"name":57,"role":36,"phone":32,"phoneExt":32,"email":32},{"type":61,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100351750","phase-3-oral-dydrogesterone-as-luteal-phase-support-in-natural-cycle-fet-100351750",false,"NCT03859921","Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET","A Randomized Double Blind Controlled Comparison of Oral Dydrogesterone as Luteal Phase Support in Natural Cycle Frozen-thawed Embryo Transfer","Inclusion Criteria:\n\n* Age of women \\\u003C43 years at the time of stimulated IVF\n* Replacing early cleavage embryos or blastocysts after thawing\n\nExclusion Criteria:\n\n* Requiring hormonal replacement cycles\n* Use of donor oocytes or embryos\n* Undergoing preimplantation genetic testing\n* Presence of hydrosalpinx not corrected surgically prior to FET\n* Refusal to join the study","FEMALE","18 Years","42 Years",{"count":73,"type":74},716,"ESTIMATED","INTERVENTIONAL",[77],"PHASE3","This randomised double-blinded controlled trial aims to compare the live birth rate in natural FET cycles with and without oral dydrogesterone as luteal phase support. The hypothesis is that the use of oral dydrogesterone will increase the live birth rate of natural cycle FET.",[80],"Subfertility","2025-06-09",{"date":83,"type":84},"2025-06-12","ACTUAL",{"date":86,"type":84},"2021-07-01",{"date":88,"type":74},"2026-11-30",{"name":5,"class":6},1]